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main contributors to this extra cost were pharmaceuticals (1,687€; 50.2%) and
in-patient care (903€; 26.9%). The proportion of patients with other co-morbidities
leading to full coverage was not significantly different in the RA group versus
control (39.4% versus 41.8% p0.134) although Hypertension (7.8% versus 6.7%
p0.44) was significantly more frequent. Differences for Ischemic Heart Disease
(3.0% versus 2.5%) and Depression (1.9% versus 1.4%) were positive but did not
reach statistical significance.CONCLUSIONS:The economic burden of RA in France
to the health care system is significant and apparently not associated to the pres-
ence of severe co-morbidity as identified in this database.
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OBJECTIVES: There are 6,000 hip fractures annually in Finland with a population of
5.4 million. These elderly patients (average 80y) almost always require surgery.
Among elderly, 14% are using warfarin, and the anticoagulation effect should be
reversed prior to surgery. The four approaches commonly used are: cessation of
warfarin therapy, administration of vitamin-K, Fresh Frozen Plasma (FFP) or Pro-
thrombin Complex Concentrate (PCC). These approaches have different onset
times and thus, the choice of the method used influences the delay before the
surgery can safely be performed. Delay of the operation increases the number of
preoperative hospital days, and is associated with increased mortality. PCC acts as
an antidote, and thus enables immediate operation. METHODS: There were 232
patients with acute hip fracture in Kuopio University Hospital (KUH) in 2009 with a
30 days mortality of 18 patients and delay of 16 operations. Patients in need for
warfarin reversal were estimated, as well as additional hospital days caused by the
possible delay of surgery. Medication, laboratory costs, and cost of hospitalization
due to the delay were estimated for a one year perspective. Mortality rate w/wo
delay was estimated. RESULTS: There were estimated to be 29 patients with acute
hip fracture requiring warfarin reversal in KUH annually. Among these patients,
the reversal of anticoagulation with FPP, vitamin K, or cessation of warfarin leads to
30, 30 and 116 additional hospital days per year compared to PCC. The total costs
were 22 700€, 10200 €, 156 900€ and 20 300€ with FFP, vitamin-K, cessation of war-
farin and PCC, respectively. Mortality rate was estimated to be 10.6% and 7.5%
w/wo delay, respectively. CONCLUSIONS: Delay of the acute surgical intervention
increases health care costs. The use of antidote (PCC) decreases this delay among
warfarin users, and may lead to cost savings and decrease in mortality.
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OBJECTIVES: Postoperative thrombosis is a common complication after major or-
thopaedic surgery. Standard prophylaxis is done with subcutaneous injections of
low molecular heparin. Oral anticoagulants became available for this indication in
the last years. It was the aim of this study to develop a modelling matrix consider-
ing all types of costs in order to allow for a cost-benefit-analysis comparing anti-
coagulants in the post-operative setting. METHODS: This study is a prospective,
comparing clinical observation study. 90 patients after total hip/knee replacement
were included. Quality of life (QOL) was measured by an specific score (PACT-Q®).
Also the compliance was analyzed (Morisky). Clinical/labdata as well as informa-
tion on occurrence and reason of readmittance to the hospital were collected. This
analysis evaluates the cost-benefit-ratio of the oral anticoagulant rivaroxaban
compared with subcutaneous low molecular weight heparin certoparin-sodium
from the German patients’ and society‘s perspective. RESULTS: For this study a
new method was developed. The result is a matrix, which calculates the corrected
total costs (Cc) by multiplication of direct costs (CD) with a factor FQOL represent-
ing QOL. FQOLis the difference between optimal and actual quality of life (in). By
this method, the effect of QOL and compliance on total costs and on the value of a
therapy becomes visible. By application of two anticoagulants it became apparent,
that the corrected costs for rivaroxaban where lower (22,1%) than its direct costs,
resulting in a sum advantage for the innovative drug, although direct costs were
higher (9,7%) for the oral drug.CONCLUSIONS:Medicaments enter the market with
mostly higher prices compared to the standard. The payers should evaluate, if the
more expensive pharmaceutical product saves costs during the therapeutical path-
way or if the result generates a higher quality of life for the patients which could
mean better compliance with less costs for following treatments.
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OBJECTIVES: Ankylosing spondylitis (AS) is an inflammatory disease of unknown
cause. The study evaluated the cost effectiveness of adalimumab vs. placebo, goli-
mumab vs. placebo, and adalimumab vs. golimumab in patients with active AS
from the Italian payer perspective. METHODS: A cohort Markov model was devel-
oped to estimate over a time horizon of 40 years costs and QALYs associated with
adalimumab or golimumab, when used according to existing treatment guidelines.
The analysis was based on data from two Phase III studies of adalimumab and
golimumab in active AS (combined ATLAS and Canadian trials, and GO-RAISE,
respectively). Using the trial information, patients were categorized into respond-
ers and non-responders at week 12. In the base case model, response was defined
using the ASAS 20 criterion. A univariate and probabilistic sensitivity analyses was
performed to assess the robustness of the results. RESULTS: In the base case ada-
limumab therapy estimate 1.29 more discounted QALYs per patient vs. conven-
tional therapy anda total net cost (adalimumab vs. placebo) of € 43,617 per patient
resulting in an ICER of € 33,704/QALY. The analysis performed between golimumab
vs placebo led to ICER of € 39,149 per QALY gained. Comparing adalimumab to
golimumab, adalimumab resulted in 0.12 additional QALYs and € 2,350 in savings
and is therefore considered dominant. These results were sensitive to whether the
proportion of responders were adjusted for age or non-response imputation be-
tween trials and the proportion of patients who weighed over 100 kg and would
therefore require a higher dose of golimumab to reach similar effectiveness. The
results further favored adalimumab when indirect costs were included.
CONCLUSIONS: From the Italian payer and societal (in sensitivity analysis) per-
spectives, treatment of AS with adalimumab is cost saving and more effective
compared to golimumab, and thus is dominant versus golimumab, when used
according to the general treatment guidelines.
PMS30
PHARMACOECONOMIC EVALUATION OF TOCILIZUMAB MONOTHERAPY
VERSUS ADALIMUMAB MONOTHERAPY IN REDUCING DISEASE ACTIVITY IN
PATIENTS WITH RHEUMATOID ARTHRITIS
Navarro sarabia F1, Blanco FJ2, Álvaro-Gracia J3, García Meijide J4, Poveda J5,
Ruiz-beato E6
1H. Universitario Virgen Macarena, Sevilla, Andalucia, Spain, 2INIBIC-Hospital Universitario A
Coruña, A Coruña, Galicia, Spain, 3H. Universitario La Princesa, Madrid, Madrid, Spain, 4H.
Ntra. Sra. La Esperanza, Santiago de Compostela, Galicia, Spain, 5Hospital Universitario La Fe,
Valencia, Valencia, Spain, 6Roche Farma, S.A., Madrid, Madrid, Spain
OBJECTIVES: ADACTA trial (Gabay C et al EULAR June 2012) showed that tocili-
zumab (TCZ) monotherapy was superior to adalimumab (ADA) monotherapy in
reducing signs and symptoms of adult rheumatoid arthritis (RA) patients who were
either intolerant to methotrexate (MTX) or for whom continued MTX treatment
was inappropriate. The aim of the current study was to develop a cost-effective-
ness analysis of TCZ vs. ADA in MTX-intolerant/contraindicated patients.
METHODS: Economic evaluation based on ADACTA study was conducted to esti-
mate the incremental cost-effectiveness ratio (ICER) of TCZ vs. ADA. Time horizon
was 24 weeks. Patient’s response in the model was measured through ACR re-
sponse (ACR20/ACR50/ACR70) and DAS28 remission. Results were presented as
incremental cost of TCZ vs. ADA per response. The analysis was conducted from
the perspective of the Spanish National Healthcare System, considering drug costs.
Unitary costs (€, 2012) were obtained from a Spanish database. Simple univariate
sensitivity analyses were performed. RESULTS: ACR20 response rates were
achieved in 65% and 49.4% in the TCZ and ADA group respectively (p0.01). ACR50
response rates were achieved in 47.2% and 27.8% in TCZ and ADA group (p0.01)
and ACR70 response rates in 32.5% and 17.9% in TCZ and ADA group (p0.01)
respectively. DAS28 Remission was achieved in 39.9% and 10.5% in TCZ and ADA
group (p0.0001). Treatment with TCZ provided better results in cost per response
than ADA over 24 weeks in terms of ACR response (ACR20 €8,105 and €11,553;
ACR50 €11,162 and €20,382; ACR70 €15,965 and €31,705) and DAS 28 remission
€13,509 and €54,352 respectively. TCZ was dominant over ADA in ACR response and
DAS28 remission. Sensitivity analysis confirmed the stability of the results.
CONCLUSIONS: The results of this analysis suggest that TCZ monotherapy repre-
sents an efficient and cost-effective strategy vs. ADA in Spain, for treating RA
patients who are MTX intolerant/contraindicated.
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OBJECTIVES: The introduction of new biologic treatments has therefore dramati-
cally changed the therapeutic management of PsAThe objective of this study was
to determine the cost-effectiveness of biologic drugs for patients with moderate to
severe psoriatic arthritis (PsA) in Italy. METHODS: ACR and PASI response rates
from 8 randomized controlled trials were considered as indicators for clinical effi-
cacy. Short-term efficacy was based on relative probabilities of achieving ACR20
and PASI75 response in a meta-analysis. Published evidence and assumptions
were used to predict long-term efficacy. Treatment benefits were determined by
the relationship between HAQ and PASI with the EuroQoL 5D. Costs included drug
acquisition, administration, monitoring and hospitalisation. ICERs were calculated
by ordering treatments by QALYs, and comparing each treatment sequentially. A
40 year time horizon was considered, looking at the Italian perspective. RESULTS:
After palliative care, Golimumab was estimated to produce the next most QALYs.
However, in comparison to Golimumab, Adalimumab was estimated to provide an
additional 0.074 QALYs at less cost and so is a dominating strategy. In comparison
to palliative care, Adalimumab had an ICER of € 15,970 per QALY. Etanercept was
estimated to give similar additional QALYs and costs to Adalimumab. Infliximab
was estimated to provide 0.057 QALYs more than Etanercept, but this came with €
6,938 additional cost, giving Infliximab an ICER of € 121,806 per QALY versus Etan-
ercept. A number of one-way sensitivity analyses were performed finding various
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